MARCO MORSOLINI

Dr. MARCO MORSOLINI

Cardiac Surgery, IRCCS ISMETT-UPMC, Palermo, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
JPJoanna Pepke-Zaba
Joanna Pepke-Zaba
MDMarion Delcroix
Marion Delcroix
ILIrene Lang
Irene Lang
EMEckhard Mayer
Eckhard Mayer
PJPavel Jansa
Pavel Jansa
GSGérald Simonneau
Gérald Simonneau
Background—: Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics and current management of patients enrolled in an international CTEPH registry was investigated. Methods and Results—: The international registry included 679 newly diagnosed (≤6 months) consecutive patients with CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1 months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and 5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%– 60.9% across countries) underwent surgery. Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and hemodynamics. A history of acute pulmonary embolism was reported for 74.8% of patients (77.5% operable, 70.0% nonoperable). Associated conditions included thrombophilic disorder in 31.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% nonoperable). At the time of CTEPH diagnosis, 37.7% of patients initiated at least 1 pulmonary arterial hypertension–targeted therapy (28.3% operable, 53.8% nonoperable). Pulmonary endarterectomy was performed with a 4.7% documented mortality rate. Conclusions—: Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions. Operability rates vary considerably across countries, and a substantial number of patients (operable and nonoperable) receive off-label pulmonary arterial hypertension–targeted treatments.

1 March 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
MDMarion Delcroix
Marion Delcroix
ILIrene Lang
Irene Lang
JPJoanna Pepke-Zaba
Joanna Pepke-Zaba
PJPavel Jansa
Pavel Jansa
ADAndrea M. D’armini
Andrea M. D’armini
GSGérald Simonneau
Gérald Simonneau
Background—: Chronic thromboembolic pulmonary hypertension, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary arteries combined with small-vessel arteriopathy. It can be cured by pulmonary endarterectomy, and can be clinically improved by medical therapy in inoperable patients. A European registry was set up in 27 centers to evaluate long-term outcome and outcome correlates in 2 distinct populations of operated and not-operated patients who have chronic thromboembolic pulmonary hypertension. Methods and Results—: A total of 679 patients newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively included over a 24-month period. Estimated survival at 1, 2, and 3 years was 93% (95% confidence interval [CI], 90–95), 91% (95% CI, 87–93), and 89% (95% CI, 86–92) in operated patients (n=404), and only 88% (95% CI, 83–91), 79% (95% CI, 74–83), and 70% (95% CI, 64–76) in not-operated patients (n=275). In both operated and not-operated patients, pulmonary arterial hypertension–targeted therapy did not affect survival estimates significantly. Mortality was associated with New York Heart Association functional class IV (hazard ratio [HR], 4.16; 95% CI, 1.49–11.62; P =0.0065 and HR, 4.76; 95% CI, 1.76–12.88; P =0.0021), increased right atrial pressure (HR, 1.34; 95% CI, 0.95–1.90; P =0.0992 and HR, 1.50; 95% CI, 1.20–1.88; P =0.0004), and a history of cancer (HR, 3.02; 95% CI, 1.36–6.69; P =0.0065 and HR, 2.15; 95% CI, 1.18–3.94; P =0.0129) in operated and not-operated patients, respectively. Additional correlates of mortality were bridging therapy with pulmonary arterial hypertension–targeted drugs, postoperative pulmonary hypertension, surgical complications, and additional cardiac procedures in operated patients, and comorbidities such as coronary disease, left heart failure, and chronic obstructive pulmonary disease in not-operated patients. Conclusions—: The long-term prognosis of operated patients currently is excellent and better than the outcome of not-operated patients.

15 August 2008 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ACAngelo Guido Corsico
Angelo Guido Corsico
ADAndrea M. D'ARmini
Andrea M. D'ARmini
ICIsa Cerveri
Isa Cerveri
CKCatherine Marie Klersy
Catherine Marie Klersy
EAElena Ansaldo
Elena Ansaldo
MVMario Viganò
Mario Viganò
Rationale: There are few follow-up studies on long-term cardiopulmonary function after pulmonary endarterectomy (PEA), the operation of choice for chronic thromboembolic pulmonary hypertension (CTEPH). Objectives: To prospectively evaluate long-term outcome of patients with CTEPH treated with PEA. Methods: Between 1994 and 2006, 157 patients (mean age 55 yr) were treated with PEA at Pavia University Hospital. The patients were evaluated before PEA and at 3 months (n = 132), 1 year (n = 110), 2 years (n = 86), 3 years (n = 69), and 4 years (n = 49) afterward by NYHA class, right heart hemodynamic, spirometry, carbon monoxide transfer factor (TlCO), arterial blood gas, and treadmill incremental exercise test. Measurements and Main Results: Cumulative survival was 84%. Within 3 months, 18 patients died in-hospital and 2 had lung transplantation; during long-term follow-up, 6 died, 1 had lung transplantation, and 3 had a second PEA (2.5 events per 100 person-years). NYHA class III–IV was the most important predictor of late death, lung transplant, or PEA redo (hazard ratio, 3.94). Extraordinary improvement in NYHA class, hemodynamic, and PaO2 were achieved in the first 3 months (P < 0.001) and persisted during follow-up; exercise tolerance progressively increased over time (P < 0.001). At 4 years, although 74% of the patients were in NYHA class I and none was in class IV, 24% had pulmonary vascular resistance greater than 500 dyne.s/cm5 or PaO2 less than 60 mm Hg; they were significantly older and were more frequently in NYHA class III–IV 3 months after surgery than the others. Conclusions: After PEA, long-term survival and cardiopulmonary function recovery is excellent in most patients.

8 November 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DJDavid P. Jenkins
David P. Jenkins
MMMichael Madani
Michael Madani
EMEckhard Mayer
Eckhard Mayer
KKKim Kerr
Kim Kerr
NKNic Kim
Nic Kim
PDPhilippe Dartevelle
Philippe Dartevelle
It is likely that chronic thromboembolic pulmonary hypertension (CTEPH) is more prevalent than currently recognised. Imaging studies are fundamental to decision making with respect to operability. All patients with suspected CTEPH should be referred to an experienced surgical centre. Currently, there is no risk scoring stratification system to guide operability assessment and it is predominantly based on surgical experience.The aim of pulmonary endarterectomy (PEA) is the removal of obstructive material to immediately reduce pulmonary vascular resistance. PEA affords the best chance of cure, but is difficult to perfect. Recognition and clearance of distal segmental and subsegmental disease is the main problem. The basic surgical techniques include: median sternotomy incision, cardiopulmonary bypass, arteriotomy incisions within pericardium, and a true endarterectomy with meticulous full distal dissection. Deep hypothermic circulatory arrest is recommended as the best means of reducing blood flow in the pulmonary artery to allow a clear field for dissection. In the recent PEACOG (PEA and COGnition) trial there was no evidence of cognitive impairment post-PEA.Reperfusion pulmonary oedema and residual pulmonary hypertension are unique post-operative complications post-PEA and are associated with increased mortality. However, in-hospital mortality is now <5% in experienced centres.

1 September 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ADAndrea M. D'Armini
Andrea M. D'Armini
MARCO MORSOLINIMARCO MORSOLINI
MARCO MORSOLINI
GMGabriella Mattiucci
Gabriella Mattiucci
VGValentina Grazioli
Valentina Grazioli
MPMaurizio Pin
Maurizio Pin
RDRoberto Dore
Roberto Dore

1 July 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
VGValentina Grazioli
Valentina Grazioli
NVNicola Vistarini
Nicola Vistarini
MARCO MORSOLINIMARCO MORSOLINI
MARCO MORSOLINI
CKCatherine Marie Klersy
Catherine Marie Klersy
GOGiulio Orlandoni
Giulio Orlandoni
ADAndrea Maria D'ARmini
Andrea Maria D'ARmini